ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: We and others have recently discovered that CML stem cells are insensitive to IM, with multiple unique features that would be expected to promote intrinsic and acquired resistance to BCR-ABL-targeted therapeutics [2, 106-109].